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Objective: The basis for clinical variation related to underlying progressive supranuclear palsy (PSP) pathology is
unknown. We performed a genome-wide association study (GWAS) to identify genetic determinants of PSP phenotype.
Methods: Two independent pathological and clinically diagnosed PSP cohorts were genotyped and phenotyped to
create Richardson syndrome (RS) and non-RS groups. We carried out separate logistic regression GWASs to compare
RS and non-RS groups and then combined datasets to carry out a whole cohort analysis (RS = 367, non-RS = 130). We
validated our ﬁndings in a third cohort by referring to data from 100 deeply phenotyped cases from a recent GWAS.
We assessed the expression/coexpression patterns of our identiﬁed genes and used our data to carry out gene-based
association testing.
Results: Our lead single nucleotide polymorphism (SNP), rs564309, showed an association signal in both cohorts,
reaching genome-wide signiﬁcance in our whole cohort analysis (odds ratio = 5.5, 95% conﬁdence interval = 3.2–10.0,
p = 1.7 × 10−9). rs564309 is an intronic variant of the tripartite motif-containing protein 11 (TRIM11) gene, a compo-
nent of the ubiquitin proteasome system (UPS). In our third cohort, minor allele frequencies of surrogate SNPs in high
linkage disequilibrium with rs564309 replicated our ﬁndings. Gene-based association testing conﬁrmed an association
signal at TRIM11. We found that TRIM11 is predominantly expressed neuronally, in the cerebellum and basal ganglia.
Interpretation: Our study suggests that the TRIM11 locus is a genetic modiﬁer of PSP phenotype and potentially adds fur-
ther evidence for the UPS having a key role in tau pathology, therefore representing a target for disease-modifying therapies.
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Progressive supranuclear palsy (PSP) is a progressiveneurodegenerative condition and the most common
cause of atypical parkinsonism, with an estimated
prevalence of 5 to 7 per 100,000.1 The pathology of PSP
is centered on the structural microtubule-associated pro-
tein tau, encoded by the MAPT gene located on
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chromosome 17. In PSP, there is neuronal and glial accu-
mulation of hyperphosphorylated ﬁbrillary aggregates of
4-repeat predominant tau. The pathological hallmarks of
PSP include a high density of neuroﬁbrillary tangles and
neuropil threads in the basal ganglia and brainstem along
with tau-positive tufted astrocytes.2
Richardson syndrome (RS) is the most common
clinical phenotype related to PSP pathology. It was ﬁrst
described by Steele, Richardson, and Olszewski as an L-
dopa–unresponsive akinetic–rigid syndrome with falls, a
vertical supranuclear gaze palsy, and dementia.3 Previous
studies looking at the natural history of RS have shown
that the mean age of disease onset is 65 to 67 years, and
the median disease duration is 6 to 7 years.4 In addition, a
clinical diagnosis of RS has been shown to be highly pre-
dictive of underlying PSP pathology,5 and the diagnosis of
this form of PSP was operationalized in the NINDS–
Society for Progressive Supranuclear Palsy criteria.6
We and others have identiﬁed alternative clinical
phenotypes7,8 related to PSP pathology in relatively small
case series. This led to the description of 2 distinct PSP
non-RS clinical phenotypes by Williams and colleagues,
PSP-parkinsonism (PSP-P)9 and pure akinesia with gait
freezing (PAGF).10 PSP-P and PAGF have a similar age of
disease onset to RS, clinically resemble RS in the latter
stages of disease, and have a signiﬁcantly longer mean dis-
ease duration (PSP-P = 9 years, PAGF = 13 years). The
basis for this clinical variation related to a core pathology
is unknown. PSP clinical subtypes have been related to
the regional distribution and severity of pathogenic tau
accumulation and neuronal loss.11 Although postmortem
remains the gold standard for diagnosing PSP, recent pub-
lication of new diagnostic criteria from the Movement
Disorder Society (MDS) PSP study group12 highlight the
presence of PSP-P and PAGF along with other PSP clini-
cal phenotypes relating to underlying PSP pathology
including PSP-corticobasal (PSP-CBS)13 and PSP-frontal
(PSP-F) subtypes.14
A recent comprehensive genome-wide association
study (GWAS) involving 1,114 pathologically conﬁrmed
PSP cases and 3,247 controls was carried out to identify
common risk variants for PSP. Single nucleotide polymor-
phisms (SNPs) that passed a signiﬁcance cutoff point of
p ≤ 10−3 were subsequently genotyped in a validation
cohort that consisted of 1,051 clinically diagnosed PSP
cases and 3,560 controls. Loci at MAPT (H1 haplotype
and H1c sub-haplotype), MOBP, STX6, and EIF2AK3
were associated with PSP.15
Differences in the clinicopathological phenotypes of
tauopathies (including Alzheimer disease) may relate to
differences in the strain properties of toxic tau species.16
However, here we use a large clinicopathological cohort
based on the latest MDS diagnostic criteria to show that
the clinical phenotype of PSP relates in part to genetic var-
iants that may determine regional susceptibility.
Subjects and Methods
Study Design and Participants
All patients gave written informed consent for the use of their
medical records and blood/brain tissue for research purposes,
including the analysis of DNA. Patients with a neuropathological
diagnosis of PSP were identiﬁed from the following UK brain
banks: MRC London Neurodegenerative Diseases Brain Bank
(Research Ethics Committee reference 08/MRE09/38 + 5), Mul-
tiple Sclerosis and Parkinson’s UK Brain Bank, London
(Research Ethics Committee reference 08/MRE09/31 + 5), and
Queen Square Brain Bank (the brain donor program was
approved by a London Multi-Centre Research Ethics Commit-
tee, and tissue is stored for research under a license from the
Human Tissue Authority, No. 12198). The year of death for
cases ranged from 1998 to 2017.
Patients with a clinical diagnosis of a PSP syndrome were
identiﬁed from the Progressive Supranuclear Palsy Cortico-Basal
Syndrome Multiple System Atrophy Longitudinal UK
(PROSPECT-UK) study, a longitudinal study of patients with
atypical parkinsonian syndromes undergoing serial clinical, imag-
ing, and biomarker measures (Queen Square Research Ethics
Committee 14/LO/1575). Cases were recruited between 2015
and 2017. A subset of these patients also underwent postmortem
neuropathological diagnosis at the Queen Square Brain Bank.
Phenotyping of Cases
Retrospective clinical notes review of all neuropathological PSP
cases was performed to extract the following demographic and
clinical information: gender, age at motor symptom onset, date
of motor symptom onset, and date of death. This information
was used to calculate the total disease duration (deﬁned as date
of death − date of motor symptom onset). Cases that did not
have the above clinical information available were excluded from
the study. Exclusion criteria used in the MDS diagnostic criteria
were not considered, as the presence of alternative diseases would
have been identiﬁed at postmortem. Using the MDS diagnostic
criteria, each case was assigned an initial and ﬁnal clinical pheno-
type.12 This was based on the clinical features documented in
clinical letters in the ﬁrst 3 years from motor symptom onset
and the clinical features documented in clinical letters in the last
2 years of life. We focused on 3 clinical phenotypes of interest:
RS, PSP-P, and PAGF; and only assigned these phenotypes if
their corresponding “probable” criteria were fulﬁlled. Cases were
assigned a diagnosis of “unclassiﬁed” if there was insufﬁcient evi-
dence from the clinical notes to assign one of the phenotypes of
interest. In cases where there was an overlap of clinical pheno-
type features, a consensus decision was made to assign the most
appropriate clinical phenotype. The same clinical data as above
were collected on clinically diagnosed PSP cases using their
PROSPECT-UK study clinical assessments. To ensure accuracy
in assigning a phenotype, living subjects were only included if
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their latest clinical assessment was carried out at least 3 years
after motor symptom onset. In addition, cases were excluded
from analyses if they had the presence of any MDS diagnostic
exclusion criteria or if they fulﬁlled both MDS criteria for one of
our PSP phenotypes of interest as well as Armstrong criteria for
probable PSP-CBS, as these subjects may have underlying corti-
cobasal degeneration pathology.17
Genotyping and Quality Control
All pathologically diagnosed cases had DNA extracted from fro-
zen brain tissue (cerebellum or frontal cortex). Subsequently,
DNA samples from all cases underwent genotyping using the
Illumina (San Diego, CA) NeuroChip.18 Standard genotype data
quality control steps were carried out as per Reed et al,19 includ-
ing a principal component analysis (PCA) to exclude all
non-European subjects. All cases were screened for known
MAPT, LRRK2, and DCTN1 mutations covered by the Neuro-
Chip. SNP imputation was carried out on our NeuroChip data
using the Sanger Imputation Service to produce a ﬁnal list of
common (minor allele frequency ≥ 1%) variants for analyses.
Imputed SNP positions were based on Genome Reference Con-
sortium Human 37/human genome version 19 (GRCh37/hg19).
Standard quality control steps taken for SNP imputation were
carried out as per Reed et al.19
To conﬁrm the validity of our NeuroChip genotyping and
imputation, a subset of both directly genotyped and imputed
SNPs underwent regenotyping using the LGC KASP genotyping
service for coverage of signiﬁcant regions in association.
Statistical Analyses
All statistical analyses were carried out using Plink v1.9 and
images generated using R v3.3.2 and LocusZoom.
By dividing the whole cohort into RS and non-RS (com-
bined PSP-P and PAGF) groups based on their initial clinical
phenotype, group comparisons of clinical features were carried
out using t tests. In addition, the RS and non-RS group minor
allele frequencies (MAFs) of all PSP case–control GWAS risk
variants were extracted from our imputed data.
Logistic Regression GWAS
A logistic regression GWAS was performed on our imputed data
to compare RS and non-RS groups. Based on their assigned ini-
tial clinical phenotypes, non-RS subjects were deﬁned as “cases”
and RS subjects were deﬁned as “controls.” The regression model
used gender, age at motor symptom onset, study site of subject
recruitment, and the ﬁrst 2 principal components as covariates.
This analysis was ﬁrst carried out on our pathological cohort and
then subsequently on our clinical cohort before combining data-
sets to carry out a whole cohort analysis. The Bonferroni correc-
tion for multiple SNP testing was used to set the genome-wide
signiﬁcance p value threshold at 9 × 10−9. The whole cohort
GWAS analysis was used to generate Manhattan and regional
association plots.
All signiﬁcant SNPs from our association analysis were
assessed for their MAFs in European controls. This data
was acquired from the Genome Aggregation Database (gnomad.
broadinstitute.org), which is based on data from 120,000
exome sequences and 15,500 whole genome sequences from
unrelated individuals.
All signiﬁcant SNPs from our association analysis were
assessed for their level of signiﬁcance in phase 1 of the original
PSP case–control GWAS15 using publicly available data at the
National Institute on Aging Genetics of Alzheimer’s Disease
Data Storage Site (www.niagads.org).
PSP Case–Control GWAS Validation Cohort
A separate subset of 100 pathologically conﬁrmed PSP cases
from phase 1 of the original PSP case–control GWAS had in-
depth phenotype data available to assign an initial clinical pheno-
type according to the MDS criteria, as per our study methods.
These cases had undergone genotyping using the Illumina
Human 660W-Quad Inﬁnium Beadchip with standard data
quality control steps taken, including a PCA to exclude
non-Europeans. RS and non-RS group MAFs for directly geno-
typed SNPs that were signiﬁcant in our phenotype GWAS were
extracted to further validate our ﬁndings.
Gene-Based Association Testing
Gene-level p values were calculated using MAGMA v1.06 as out-
lined in de Leeuw et al.20 MAGMA tests the joint association of
all SNPs in a gene with the phenotype while accounting for link-
age disequilibrium (LD) between SNPs. This presents a powerful
alternative to SNP-based analyses, as it reduces the multiple test-
ing burden and thus increases the possibility of detecting effects
consisting of multiple weaker associations.20 SNPs were mapped
to genes using National Center for Biotechnology Information
(NCBI) deﬁnitions (GRCh37/hg19, annotation release 105);
only genes in which at least one SNP mapped were included in
downstream analyses. These were run both with and without a
window of 35kb upstream and 10kb downstream of each gene,
as most transcriptional regulatory elements fall within this inter-
val.21 Furthermore, the major histocompatibility complex region
was excluded. The gene p value was computed based on the
mean association statistic of SNPs within a gene, with genome-
wide signiﬁcance set to p < 2.74 × 10−6, and LD was estimated
from the European subset of 1000 Genomes Phase 3.
Whole Exome Sequencing
Sixty-nine cases from our pathological cohort had previously
undergone whole exome sequencing (WES) using the Illumina
Truseq Capture in Illumina HiSeq platform. These data were
used to look for the presence of rare coding variants in genes of
interest to arise from our GWAS. Read data were aligned to
hg19 by use of novoalign (v3.02.04) and indexed bam ﬁles were
deduplicated of polymerase chain reaction artifacts by use of
Picard Tools MarkDuplicates. The Genome Analysis Toolkit
was then used to perform all subsequent steps according to their
good practice; local realignments around possible indels and vari-
ant calling were conducted with HaplotypeCaller. Variants were
ﬁltered by use of variant quality score recalibration (truth
tranche = 99.0%). In addition, hard-ﬁltering based on low-depth
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and low-genotype quality was performed. Annotation was per-
formed by use of Annovar software.
Assessment of Gene Expression
Gene expression proﬁles were assessed using publicly available
BRAINEAC (www.braineac.org),22 GTEx (www.gtexportal.org),
and Allen Brain Atlas (www.brain-map.org)23 Web-based resources.
The BRAINEAC database contains brain tissues from
134 healthy controls from the following brain regions: frontal
cortex, temporal cortex, parietal cortex, occipital cortex, hippo-
campus, thalamus, putamen, substantia nigra, medulla, cerebel-
lum, and white matter. RNA isolation and processing of brain
samples were performed and analyzed using Affymetrix (Santa
Clara, CA) Exon 1.0 ST arrays. The GTEx database consists of
8,555 samples from 53 tissues (including 13 brain regions) of
544 donors for which RNAseq was conducted. The GTEx Pro-
ject was supported by the Common Fund of the Ofﬁce of the
Director of the National Institutes of Health, and by the
National Cancer Institute, National Human Genome Research
Institute, National Heart, Lung, and Blood Institute, National
Institute on Drug Abuse, National Institute of Mental Health,
and NINDS. The data used for the analyses described in this arti-
cle were obtained from the GTEx Portal on April 31, 2018. The
Allen Human Brain Atlas database contains microarray data from
8 neuropathologically normal individuals of varying ethnicity.
Microarray data were generated using the Agilent Technologies
(Santa Clara, CA) 4 × 44 Whole Human Genome array and
covers 62,000 gene probes per proﬁle and 150 brain regions.
Gene expression at the cellular level in the brain was ana-
lyzed using RNAseq data from the Brain RNA-Seq database
(www.brainrnaseq.org/) as per Zhang et al.24 Of note, these
data were generated from healthy temporal lobe samples that
were resected from 14 patients to gain access to deeper epileptic
hippocampi. The number of different cell types obtained from
these samples were as follows: mature astrocyte, n = 12; micro-
glia, n = 3; neuron, n = 1; oligodendrocyte, n = 3. We also
used single cell RNA-Seq data provided by DropViz (www.
dropviz.org), which provides gene expression on 690,000 indi-
vidual cells derived from 9 different regions of the adult mouse
brain.25
TABLE 1. Clinical Features of Subjects Included in Genotype–Phenotype Analyses
Feature Pathological Cohort Clinical Cohort Whole Cohort
RS Non-RS RS Non-RS RS Non-RS
Subjects, n 230 76,
PSP-P = 60,
PAGF = 16
137 54,
PSP-P = 42,
PAGF = 12
367 130,
PSP-P = 102,
PAGF = 28
Male, % 60.0 53.9 57.7 51.9 59.1 53.1
Age at motor
symptom onset,
yr, mean, range, SD
68.9,
49–89,
7.4
65.9,
46–86,
8.8
66.5,
51–87,
6.8
65.3,
54–82,
6.9
68.1,a,b
49–89,
7.3
65.6,a,b
46–86,
8.0
Final/current clinical
phenotype
RS = 230 RS = 71,
PSP-P = 4,
PAGF = 1
RS = 137 RS = 28,
PSP-P = 20,
PAGF = 6
RS = 367 RS = 99,
PSP-P = 24,
PAGF = 7
Mean disease
duration in deceased
subjects, yr, mean,
range, SD
5.9,
1.9–15.9,
1.9
10.7,
2.2–16.3,
2.9
5.6,
2.4–13.5,
2.2
9.2,
8.1–10.8,
1.2
5.8,b,c
1.9–15.9,
1.9
10.6,b,c
2.4–13.5,
2.8
Subjects undergoing
postmortem,
n (% with a
pathological
diagnosis of PSP)
230 (100) 76 (100) 10 (100) 1 (100) 240 (100) 77 (100)
RS/non-RS status is based on initial clinical phenotype.
aNo statistically signiﬁcant difference between RS and non-RS groups.
bNo statistically signiﬁcant difference between pathological and clinical cohorts.
cStatistically signiﬁcant (p < 0.05) difference between RS and non-RS groups using Welch t test.
PAGF = pure akinesia with gait freezing; PSP = progressive supranuclear palsy; PSP-P = PSP-parkinsonism; RS = Richardson syndrome; SD = stan-
dard deviation.
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Colocalization Analyses
To evaluate the probability that the same causal SNP was
responsible for modifying the phenotype of PSP and modulating
gene expression, we performed the Coloc method described by
Giambartolomei et al,26 using our GWAS summary statistics
coupled with expression quantitative trait loci (eQTLs) from
Braineac and GTEx. GTEx eQTLs included those originating
from all brain regions. We restricted analyses to genes within
1Mb of the signiﬁcant region of interest (p < 5 × 10−8) and ran
coloc.abf with default priors. We considered tests with a Poste-
rior probability of hypothesis 4 (PPH4) ≥ 0.75 to have strong
evidence for colocalization.
Results
A total of 497 subjects were included for analyses. Their
clinical features are summarized by cohort and disease
group in Table 1. Forty-four subjects were deemed unclas-
siﬁable and therefore not included in subsequent analyses.
An initial screen of our genotype data revealed simi-
lar MAFs for risk variants identiﬁed in the PSP case–
control GWAS (Table 2).
In addition, none of our cases carried known patho-
genic variants covered by the NeuroChip for the following
genes: MAPT (40 variants), LRRK2 G2019S (1 variant),
and DCTN1 (12 variants). After SNP imputation and
data quality control, 6,215,948 common variants were
included in our analysis. Assigning non-RS subjects as
“cases” and RS subjects as “controls,” we applied a logistic
regression association analysis using gender, age at motor
symptom onset, study site of subject recruitment, and the
ﬁrst 2 principal components as covariates. We ﬁrst carried
out this analysis using data from our pathological cohort
and then validated our ﬁndings using data from our inde-
pendent clinical cohort before combining both datasets for
a whole cohort analysis. The whole cohort analysis
revealed 27 SNPs, all located on chromosome 1, which
passed the threshold for genome-wide signiﬁcance
(p < 9 × 10−9). These results are summarized in Figure 1.
Population stratiﬁcation was not evident in our cohort, as
non-European subjects were excluded from analyses as
part of our genotype data quality control. This was further
conﬁrmed by obtaining a genomic inﬂation factor
(lambda) value of 1.05. A further locus on chromosome
12 approached genome-wide signiﬁcance with the lead
SNP (rs621042) p = 7.8 × 10−7.
An in-depth analysis of our signiﬁcant SNPs reveal that
they are all in high LD with each other (as deﬁned by r2 > 0.80)
and are all located at the chromosome 1q42.13 locus. A regional
association plot (Fig 2) reveals that our lead SNP, rs564309, is an
intronic variant located between exons 3 and 4 of the tripartite
motif-containing protein 11 (TRIM11) gene. Alongside our
directly genotyped lead SNP, the imputation quality score for
imputed signiﬁcant SNPs ranged from 0.96 to 1. Ninety-six cases
from our pathological cohort underwent regenotyping for 8 SNPs
(rs564309, rs35670307, rs12065815, rs10158354, rs3795811,
rs6426503, rs138782220, and rs7555298) that span the
TABLE 2. Comparison of PSP Risk Variant Status between PSP Case–Control GWAS and PSP Phenotype GWAS
Data
Chr. band SNP Position, bp Gene PSP Case–Control GWAS PSP Phenotype GWAS
MAF in Healthy
Controls
MAF
in PSP
MAF
in RS
MAF in
Non-RS
1q25.3 rs1411478,
180,962,282
STX6 0.42 0.50 0.44a 0.43
2p11.2 rs7571971,
88,895,351
EIF2AK3 0.26 0.31 0.34a 0.30
3p22.1 rs1768208,
39,523,003
MOBP 0.29 0.36 0.32a 0.32
17q21.31 rs8070723,
44,081,064
MAPT
(H1 haplotype)
0.23 0.05 0.05a 0.05
rs242557,
44,019,712
MAPT (H1c
subhaplotype)
0.35 0.53 0.44a 0.49
PSP case–control GWAS data taken from Hoglinger et al.15
aNo statistically signiﬁcant difference between RS and non-RS groups using Fisher exact test.
Chr. = chromosome; GWAS = GWAS; MAF = minor allele frequency; PSP = progressive supranuclear palsy; RS = Richardson syndrome; SNP = sin-
gle nucleotide polymorphism.
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signiﬁcant chromosome 1q42.13 locus. Three of the 8 SNPs,
including our lead SNP, were originally directly genotyped via
the NeuroChip, whereas the remaining 5 SNPs were originally
imputed in our dataset. The p value of these SNPs in our whole
cohort GWAS ranged from 1.7 × 10−9 to 7.3 × 10−5. The
results of this regenotyping run showed 100% concordance with
our original NeuroChip and imputation data.
Furthermore, 3 of the signiﬁcant SNPs in LD with
rs564309 are nonsynonymous (missense) coding variants
of the Obscurin (OBSCN) gene. OBSCN is mainly
expressed in skeletal muscle and may have a role in the
organization of myoﬁbrils during assembly as well as
mediating interactions between the sarcoplasmic reticulum
and myoﬁbrils.27 Related diseases include ﬁbromuscular
dysplasia and hypertrophic obstructive cardiomyopathy.
The association statistics for rs564309, and the most
signiﬁcant ﬂanking SNPs located at neighboring genes
within the chromosome 1q42.12 locus, are summarized
FIGURE 1: Manhattan plot of whole cohort Richardson syndrome (RS) versus non-RS association analysis, highlighting genome-wide
signiﬁcance at chromosome 1. The red line indicates the threshold for genome-wide signiﬁcance (p < 9 × 10−9). GWAS = genome-wide
association study; PSP = progressive supranuclear palsy.
FIGURE 2: Regional association plot of Richardson syndrome (RS) versus non-RS association analysis using imputed single
nucleotide polymorphism (SNP) data, implicating the chromosome 1q42.13 locus and identifying rs564309, an intronic variant of
TRIM11, as our lead SNP. SNP positions, recombination rates, and gene boundaries are based on GRCh37/hg19.
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below (Table 3). The MAF of these SNPs was shown to be
0.10 in healthy European controls in the gnomAD database.
To explore the impact of inadvertently including
Parkinson disease (PD) cases in our clinically diagnosed
non-RS group, we referred to genotyping data from
484 European clinically diagnosed PD cases that were
genotyped alongside our PSP cases and had undergone the
same quality control steps outlined above. We found that
the MAF of rs564309 in PD cases was 7%, similar to the
MAF in healthy controls and considerably lower than the
MAF in our non-RS group.
When referring to publicly available p value data
from phase 1 of the original PSP case–control GWAS, we
found that none of our signiﬁcant SNPs reached even
nominal signiﬁcance (p < 0.05). One hundred European
pathologically conﬁrmed PSP cases from this GWAS
underwent retrospective phenotyping according to the
MDS diagnostic criteria using available clinical notes. Of
those, 83 cases fulﬁlled probable criteria for initial clinical
phenotypes of relevance to this study (PSP-RS, n = 45;
PSP-P, n = 38). rs1188473, a SNP that was directly geno-
typed in the case–control GWAS, in high LD with our
lead SNP (r2 1.0) and found to be signiﬁcant in our phe-
notype GWAS (p = 2.6 × 10−9), was shown to have simi-
lar MAFs when comparing the GWAS datasets in both
RS (4% vs 6%) and non-RS (16% vs 16%) groups, there-
fore further validating our ﬁndings.
Analysis of WES data from 65 subjects (49 RS,
16 non-RS) within our pathological cohort did not
identify any nonsynonymous coding variants in TRIM11
or TRIM17 genes.
MAGMA analyses (Fig 3) revealed that 4 genes
passed genome-wide signiﬁcance in analyses run with and
without 35kb upstream and 10kb downstream of each
gene (TRIM11, p = 5.64 × 10−9; TRIM17, p =
8.99 × 10−9; HIST3H3, p = 1.29 × 10−8; LOC101927401,
p = 5.72 × 10−8). LOC101927401 appeared only in
NCBI annotation and was absent in the queried gene
expression databases; thus, it was excluded in downstream
analyses.
We then used human brain gene expression and
coexpression data from the BRAINEAC, GTEx, and Allen
Atlas databases to assess the expression proﬁles of genes
identiﬁed in our MAGMA analysis: TRIM11, TRIM17,
and HIST3H3. All 3 datasets revealed high levels of
TRIM11 and TRIM17 expression in the brain, particularly
cerebellum and putamen, whereas HIST3H3 expression
appeared to be at the lower limit of detection in human
brain (Fig 4).
We explored the cellular speciﬁcity of TRIM11,
TRIM17, and HIST3H3 expression in human brain using
data provided by the Brain RNA-Seq database. This dem-
onstrated higher neuronal expression (n = 1) of TRIM11
(0.38FPKM) compared to both TRIM17 (0.12FPKM)
and HIST3H3 (0.10FPKM), which was expressed at the
lower limit of detection. In comparison to its neuronal
expression, TRIM11 expression in glial cell types was
lower (mature astrocytes, 0.14 ± 0.02FPKM, n = 12;
TABLE 3. RS versus Non-RS Association Statistics for rs564309, and the Most Signiﬁcant Flanking SNPs Located
at Neighboring Genes, in Pathological, Clinical, and Whole Cohorts, Respectively
SNP
Position, bp Gene Pathological Cohort Clinical Cohort Whole Cohort
MAF
in RS
MAF in
Non-RS
OR
(95% CI)
MAF
in RS
MAF in
Non-RS
OR
(95% CI)
OR
(95% CI) pa
rs564309,
228,585,562
TRIM11 0.04 0.19 6.25b
(3.12–12.5)
0.04 0.16 4.76b
(1.96–12.5)
5.55
(3.22–10.0)
1.7 × 10−9
rs61827276,
228,597,130
TRIM17 0.04 0.18 5.88b
(2.78–12.5)
0.04 0.16 5.55b
(2.17–14.3)
5.55
(3.12–10.0)
6.2 × 10−9
rs61825312,
228,530,748
OBSCN 0.04 0.19 5.88b
(2.86–12.5)
0.04 0.16 4.35b
(1.78–11.1)
5.26
(2.94–9.09)
7.1 × 10−9
rs2230656,
228,612,838
HIST3H3 0.06 0.23 4.35b
(2.32 –8.33)
0.06 0.20 3.70b
(1.75–8.33)
4.00
(2.50–6.67)
1.3 × 10−8
SNP positions are based on GRCh37/hg19.
aProbability value in whole cohort analysis.
bp > 9 × 10−9.
CI = conﬁdence interval; MAF = minor allele frequency; Non-RS = combined PSP-parkinsonism and pure akinesia with gait freezing group; OR =
odds ratio; PSP = progressive supranuclear palsy; RS = PSP-Richardson syndrome group; SNP = single nucleotide polymorphism.
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microglia, 0.12 ± 0.02FPKM, n = 3; oligodendrocytes,
0.11 ± 0.01FPKM, n = 3). We also explored cell-speciﬁc
expression of the TRIM11 and TRIM17 mouse ortholo-
gues across the brain using single cell RNA-Seq data
(http://dropviz.org/) generated from mouse brain tissue.
These data suggested that expression of TRIM11 was
highest in the spiny projection neurons (SPNs) of the stri-
atum, with high expression in SPNs of both the “direct”
and “indirect” pathways. In contrast, TRIM17 expression
was generally lower, with the highest expression detected
in the neurons of the substantia nigra.
Our colocalization analysis did not reveal any signiﬁ-
cant associations between our GWAS signals and eQTL
data in the BRAINEAC and GTEx databases in all brain
regions. However, of note, expression analyses using
GTEx data revealed that several SNPs from the chromo-
some 1q42.13 locus reaching genome-wide signiﬁcance in
our GWAS were signiﬁcant eQTLs for TRIM11 and
TRIM17 in skin and thyroid tissues when analyzed
individually.
Discussion
To our knowledge, this is the ﬁrst GWAS of clinical phe-
notype in PSP. We show that variation at the chromo-
some 1q42.13 locus determines clinical phenotype in PSP
with a very strong effect size (odds ratio = 5.5). The valid-
ity of our GWAS results is increased by similarly sized
association signals and minor allele frequencies being
observed in 2 independent cohorts, with a genome-wide
signiﬁcant association achieved when the 2 cohorts were
combined. Furthermore, when considering the subset of
MDS criteria–phenotyped cases from the original PSP
case–control GWAS, RS and non-RS group MAFs of
directly genotyped SNPs in high LD with our lead SNP
are supportive of our ﬁndings. We are also reassured by
our PD genotyping data, which revealed that our GWAS
signal would have been attenuated if PD cases had been
inadvertently included in our clinically diagnosed non-RS
group. However, this is unlikely, as we only included
PSP-P and PAGF cases that fulﬁlled probable PSP MDS
criteria for these phenotypes. We suspect that none of our
signiﬁcant SNPs reached genome-wide signiﬁcance in the
original PSP case–control GWAS because pathologically
diagnosed PSP cases would have contained a mixture of
RS and non-RS cases. When considering our data, we can
infer that the combined MAFs of RS and non-RS cases
would have resulted in overall PSP group MAFs that were
similar to those of healthy controls. The validity of our
NeuroChip genotyping and imputation were conﬁrmed
by the additional genotyping we carried out to span the
chromosome 1q42.13 locus. The validity of our indepen-
dent cohorts is suggested by the following: (1) in both
cohorts, a majority of cases with an initial non-RS pheno-
type had a ﬁnal clinical diagnosis of RS, as previously
shown by other groups28; (2) our cohorts had similar
MAFs for risk variants identiﬁed in the PSP case–control
GWAS15; and (3) there was 100% concordance between
clinical and pathological diagnoses in our clinical cohort
for the subset of patients that had undergone postmortem
examination.
FIGURE 3: MAGMA analyses revealing signiﬁcance at TRIM11, TRIM17, and HIST3H3 genes. Gene boundaries are based on
GRCh37/hg19. Red lines indicate the threshold for genome-wide signiﬁcance (p < 2.74 × 10−6). [Color ﬁgure can be viewed at
wileyonlinelibrary.com]
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MAGMA analysis conﬁrmed signals in TRIM11,
TRIM17, and HIST3H3 genes. There was evidence for
differential regional brain expression of TRIM11 and
TRIM17. Both human and mouse RNA-Seq data revealed
high levels of neuronal TRIM11 expression. In addition, it
is likely that our GWAS was signiﬁcantly underpowered
to detect signals in our eQTL colocalization analyses.
It is important to note that SNPs within this geno-
mic locus are in high LD, as evidenced by the spread of
genome-wide signiﬁcant SNPs identiﬁed in our GWAS
FIGURE 4: TRIM11, TRIM17, and HIST3H3 brain expression in 3 databases. (A) BRAINEAC database. CRBL = cerebellum;
FCTX = frontal cortex; HIPP = hippocampus; MEDU = medulla; OCTX = occipital cortex; PUTM = putamen; SNIG = substantia
nigra; TCTX = temporal cortex; THAL = thalamus; WHMT = white matter. (B) GTEx database. (C) Allen Atlas database (Caucasian
subjects). Amg = amygdala; BF = basal forebrain; BG = basal ganglia; CAU = caudate; ET = epithalamus; HiF = hippocampal
formation; Hy = hypothalamus; MES = mesencephalon; MET = metencephalon; MY = myelencephalon; PUT = putamen;
TH = thalamus; TPM = Transcripts Per Kilobase Million. Image credit: Allen Institute.
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(see Fig 2). Therefore, it is challenging to know which
gene is driving our association signal. However, the
localization of the lead SNP in our dataset and the gene
expression proﬁles described above suggest that TRIM11
is the most likely candidate gene at the chromosome
1q42.13 locus. The eQTL proﬁle of our signiﬁcant
SNPs in GTEx, when analyzed individually, was particu-
larly interesting. The strong association between several
SNPs in high LD with rs564309 and decreasing
TRIM11 and TRIM17 expression in nonbrain tissues
highlight the concept of tissue/region/cell-speciﬁc
expression of transcripts potentially being determined by
disease state and at speciﬁc time points in development
or ageing.29 However, our data do not exclude poten-
tially important functional roles for the other transcripts
within this locus.
The major limitation of our study is that our cohort
size was relatively small compared to case–control GWAS
in PSP15 and other neurodegenerative diseases.30,31 Fur-
ther replication of our ﬁndings in larger cohorts is desir-
able, including other non-RS phenotypes such as PSP-F,
to conﬁrm the role of TRIM11 and identify genetic deter-
minants of clinical phenotype in PSP at other loci. Fur-
thermore, our lead SNP is an intronic variant that does
not pass the false discovery rate threshold for being a brain
eQTL at the genes in our locus of interest, and the only
coding variants that it is in LD with are from a gene
(OBSCN) that is unlikely to be of biological relevance to
PSP pathology. This is a common dilemma, as a majority
of risk variants identiﬁed in GWASs over the past
2 decades are not associated with coding changes in
expressed proteins.32 Furthermore, disease-associated
intronic SNPs can regulate the expression of more distant
genes. When referring to BRAINEAC and GTEx,
rs564309 was found not to be a brain eQTL at distant
genes outside of our region of interest. Functional impacts
of intronic variants may arise in modes other than gene
expression, including via splicing and methylation patterns
of targeted transcripts and proteins. It remains a challenge
to understand the functional consequences of noncoding
genetic variation linked to phenotype, and so functional
studies are vital. However, gene expression studies in post-
mortem disease tissue can be challenging to interpret
because of the confounding effects of changes on cell
populations.33
TRIM proteins are biologically plausible candidates
as determinants of clinical phenotype in PSP and promis-
ing targets for follow-up functional studies. The TRIM
family of proteins, most of which have E3 ubiquitin ligase
activities, have various functions in cellular processes
including intracellular signaling, development, apoptosis,
protein quality control, autophagy, and carcinogenesis.34
A recent study has shown that TRIM11 has a critical role
in the clearance of misfolded proteins via the ubiquitin
proteasome system (UPS), in this case pathogenic frag-
ments of both ataxin-1 (Atxn1 82q) and huntingtin pro-
tein (Httex1p 97QP).35 Other groups have shown that
lysine residues of tau are targets for polyubiquitination,
which induces proteolytic degradation of tau via the
UPS.36 Furthermore, tau accumulation has been associ-
ated with decreased proteasome activity in mouse tauopa-
thy models, suggesting a feedback loop between impaired
protein degradation, aggravated by a protein aggregate–
based impairment of proteostasis.37 These ﬁndings coin-
cide with previous studies that have identiﬁed the UPS as
a potential drug target in the treatment of neurodegenera-
tive conditions.38,39 Overexpression of TRIM17, partly
controlled by glycogen synthase kinase 3 pathways, has
been shown to initiate neuronal apoptosis in cell
models.40 This was later shown to be mediated by
increased degradation of the antiapoptotic protein, mye-
loid cell leukaemia 1 (Mcl-1), via the UPS.41
Based on our data, we hypothesize that common
variation at the chromosome 1q42.13 locus modiﬁes the
function of TRIM11 to varying degrees in speciﬁc brain
regions. In the more slowly progressing non-RS syn-
dromes, an increase in TRIM11 function may lead to
increased degradation of toxic tau species via the UPS,
therefore protecting against tau pathology. Conversely, a
decrease in protein function in the brainstem is more
likely to promote rapid accumulation of tau aggregates,
manifesting as the malignant RS phenotype of PSP.
In summary, the results of this study suggest that
common variation at the TRIM11 locus may be a genetic
modiﬁer of clinical phenotype in PSP. Our ﬁndings add
further evidence for the UPS playing a key role in tau
pathology and therefore representing a potential target for
disease-modifying therapies. Further GWASs with larger
cohorts to conﬁrm our ﬁndings and identify other genetic
signals, screening of whole genome/exome sequencing data
for rare variants in TRIM11, and follow-up functional
studies at this locus are priorities.
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